- Home
- Medical
- Allied Health Services
- Biotech in the Balance (Saving a Strategic Industry in an Age of Distrust)
Biotech in the Balance (Saving a Strategic Industry in an Age of Distrust)
List Price:
$24.99
- Availability: Confirm prior to ordering
- Branding: minimum 50 pieces (add’l costs below)
- Check Freight Rates (branded products only)
Branding Options (v), Availability & Lead Times
- 1-Color Imprint: $2.00 ea.
- Promo-Page Insert: $2.50 ea. (full-color printed, single-sided page)
- Belly-Band Wrap: $2.50 ea. (full-color printed)
- Set-Up Charge: $45 per decoration
- Availability: Product availability changes daily, so please confirm your quantity is available prior to placing an order.
- Branded Products: allow 10 business days from proof approval for production. Branding options may be limited or unavailable based on product design or cover artwork.
- Unbranded Products: allow 3-5 business days for shipping. All Unbranded items receive FREE ground shipping in the US. Inquire for international shipping.
- RETURNS/CANCELLATIONS: All orders, branded or unbranded, are NON-CANCELLABLE and NON-RETURNABLE once a purchase order has been received.
Product Details
Author:
Jeremy M. Levin
Format:
Hardcover
Pages:
192
Publisher:
Rodin Books (May 19, 2026)
Imprint:
Rodin Books
Release Date:
May 19, 2026
Language:
English
Audience:
General/trade
ISBN-13:
9781957588445
ISBN-10:
1957588446
Weight:
11.2oz
Dimensions:
5" x 8" x 0.9"
File:
Eloquence-SimonSchuster_04222026_P9988629_onix30-20260422.xml
Folder:
Eloquence
List Price:
$24.99
Pub Discount:
65
Case Pack:
40
As low as:
$19.24
Publisher Identifier:
P-SS
Discount Code:
A
Overview
“The choice to invest in vaccines rather than in weapons; in treatments for rare diseases rather than in speculative consumer products; in long-term infrastructure rather than in short-term optics—these are not technical decisions. They are moral decisions . . .”
Biotech in the Balance by Dr. Jeremy M. Levin shows why the next lifesaving medicines may not arrive on time, and what we can do about that in a period of political change. This is not a technical book. It is a bedside-to-boardroom story, told from inside the system, with a clear map of what has to change so that medicines keep arriving when people need them. When funding for research and development is politicized, trust in science erodes and the foundations of biotechnology weaken. When science is treated as a partisan symbol rather than a shared foundation for health, patients and families bear the consequences.
Dr. Levin’s career began as a scientist studying the structure of DNA, and then as a physician in university hospitals in London, Cape Town, and Geneva. As a doctor, he saw the difference between patients saved by medicines that arrived just in time, and those who were not so fortunate. That experience led to a simple conviction: drug discovery and development is not an abstract business. It is a living coalition of scientists, governments, businesses, and—above all—patients. For patients and their families, profitability and internal strategy are not the point. What matters is whether a therapy works, how quickly results can be seen, and how benefits are weighed against risks—including the risk of doing nothing.
Throughout the book, Dr. Levin keeps patients at the center of the discussion—politics, markets, supply chains, and governance—and shows how each of these forces can accelerate or delay medical progress. Written from the perspective of a scientist and physician, Biotech in the Balance argues for a resilient, globally competitive biotechnology industry built to serve patients and earn lasting public trust. It offers a call to action for preserving biotechnology as a strategic asset—and a practical framework for leaders who want to strengthen the system rather than merely defend it.
Biotech in the Balance by Dr. Jeremy M. Levin shows why the next lifesaving medicines may not arrive on time, and what we can do about that in a period of political change. This is not a technical book. It is a bedside-to-boardroom story, told from inside the system, with a clear map of what has to change so that medicines keep arriving when people need them. When funding for research and development is politicized, trust in science erodes and the foundations of biotechnology weaken. When science is treated as a partisan symbol rather than a shared foundation for health, patients and families bear the consequences.
Dr. Levin’s career began as a scientist studying the structure of DNA, and then as a physician in university hospitals in London, Cape Town, and Geneva. As a doctor, he saw the difference between patients saved by medicines that arrived just in time, and those who were not so fortunate. That experience led to a simple conviction: drug discovery and development is not an abstract business. It is a living coalition of scientists, governments, businesses, and—above all—patients. For patients and their families, profitability and internal strategy are not the point. What matters is whether a therapy works, how quickly results can be seen, and how benefits are weighed against risks—including the risk of doing nothing.
Throughout the book, Dr. Levin keeps patients at the center of the discussion—politics, markets, supply chains, and governance—and shows how each of these forces can accelerate or delay medical progress. Written from the perspective of a scientist and physician, Biotech in the Balance argues for a resilient, globally competitive biotechnology industry built to serve patients and earn lasting public trust. It offers a call to action for preserving biotechnology as a strategic asset—and a practical framework for leaders who want to strengthen the system rather than merely defend it.
